Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds, described in a study published January 14 in the open-access ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach. Two new ...

aSection of Musculoskeletal Disease, NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, ...

Nanoscope Therapeutics has reported data from a mid-stage clinical trial that suggests its optogenetic therapy based on light-sensitive molecules is an effective treatment for incurable eye ...

VP-001 is under clinical development by PYC Therapeutics and currently in Phase I for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase I drugs for Retinitis Pigmentosa (Retinitis) have ...

Scientists have identified two non-retinoid compounds that may be able to treat retinitis pigmentosa (RP), a group of inherited eye diseases that cause blindness. The compounds were discovered by ...

Data from a randomized, multicenter, sham-controlled program investigating MCO-010 (Nanoscope Therapeutics) in 27 patients with retinitis pigmentosa demonstrated “significant improvements” in ...

THE loss of dark adaptation and night blindness which characterizes the earliest stages of retinitis pigmentosa suggested to us the possibility that one of the fundamental features of the ...

vanderbilt.edu Takayasu arteritis (TA) is a rare disease affecting chiefly young women, although it can affect both men and women and persons of many different ethnicities. TA carries a high morbidity ...

Retinitis pigmentosa is a relatively rare genetic disorder (affecting 1 in 3,500 people), while age-related macular degeneration affects 7–8% of the population, and its incidence increases with age.

We present a case of Takayasu’s arteritis in a woman in her 30s, who exhibited visual symptoms and ophthalmic manifestations of the disease, specifically Takayasu’s retinopathy stage 4, in both eyes.